Oscotec Inc.

Translating science into medicine
회원가입

회원가입

로그인
PRESS

NEWSROOM

Notice Press Releases Publications IR Materials
Home NEWSROOM Press Releases
T기본글꼴
✔ 사이트를 뷰어로 보기 검색 Write

  1. Lazertinib Shows Promising Antitumor Activity in Patients With EGFR+ NSCLC

    Date2019-12-14 MediaTargeted Oncology PipelineLazertinib
    Read More

  2. More than half of Korean biopharma firms view R&D investments as assets.

    Date2018-03-14 MediaThe Korea Herald PipelineIndustry
    Read More

  3. Oscotec and Beactica Therapeutics announce license and collaboration agreement to develop new cancer drug

    Date2021-03-02 MediaCISION PipelineOscotec
    Read More

  4. Oscotec shares rebound on launch of US clinical trial

    Date2017-12-11 MediaKBR (; Korea Biomedical Review) PipelineSKI-G-801
    Read More

  5. Oscotec wins exception policy for continued R&D for new drugs

    Date2019-06-25 MediaKBR (; Korea Biomedical Review) PipelineOscotec
    Read More

  6. Oscotec`s acute leukemia treatment wins orphan drug status from FDA

    Date2018-11-23 MediaKBR (; Korea Biomedical Review) PipelineSKI-G-801
    Read More

  7. Oscotec`s SYK inhibitor Program Gets Korea Drug Fund Money

    Date2016-01-19 MediaScrip (Informa Pharma Intelligence) PipelineSYK-O-703
    Read More

  8. Oscotec/ADEL Announce FDA Clearance of IND Application of ADEL-Y01 for the Treatment of Alzheimer's Disease

    Date2023-09-14 MediaBiospace PipelineOscotec
    Read More

  9. Oscotec/ADEL Initiates First-in-Human Dosing in Ph1 of Anti-MTBR Tau Antibody ADEL-Y01 In Alzheimer's Disease

    Date2024-02-23 Mediayahoo! finance PipelineOscotec
    Read More

  10. Other news to note for March 2, 2021

    Date2021-03-02 MediaBioWorld PipelineOscotec
    Read More

  11. Profiles of Four New Stock-Billionaires

    Date2007-02-19 MediaMBN PipelineOscotec
    Read More

  12. Yuhan to start phase-3 trial on lung cancer drug Lazertinib

    Date2019-12-12 MediaKBR (; Korea Biomedical Review) PipelineLazertinib
    Read More
Board Pagination Prev 1 2 3 Next
/ 3
© k2s0o1d6e0s8i2g7n. ALL RIGHTS RESERVED.
서버에 요청 중입니다. 잠시만 기다려 주십시오...